PharVision Advisers’s Rithm Capital RITM Stock Holding History

PharVision Advisers’s Portfolio RITM Stock Details RITM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,025	Closed	-$273K	–	531
2025 Q4	$273K	Buy	25,025 +356	+1%	+$3.93K	0.14%	334
2025 Q3	$281K	Buy	24,669 +7,674	+45%	+$93K	0.16%	264
2025 Q2	$192K	Sell	16,995 -28,510	-63%	-$314K	0.28%	211
2025 Q1	$521K	Buy	45,505 +33,795	+289%	+$391K	0.72%	13
2024 Q4	$127K	Buy	+11,710	New	+$127K	0.11%	360

Other funds holding RITM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

PharVision Advisers's RITM Position: Q1 2026 in Review

PharVision Advisers sold out of Rithm Capital (RITM) in Q1 2026, closing a stake of 25,025 shares — an estimated $273K sold.

PharVision Advisers first reported a position in RITM in Q4 2024 and held it in 5 quarters. The position peaked at $521K in Q1 2025. 522 funds tracked by Wall St. Rank hold RITM as of Q1 2026.

PharVision Advisers reported no remaining Rithm Capital position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 25,025 Rithm Capital shares in Q1 2026, an estimated $273K.
PharVision Advisers first reported a position in Rithm Capital in Q4 2024 and held it in 5 quarters.
PharVision Advisers's Rithm Capital position peaked at $521K in Q1 2025.
522 funds tracked by Wall St. Rank held Rithm Capital as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.